【baked potatoes on the traeger】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference

Encyclopedia 2024-09-29 12:18:20 139

NEW YORK,baked potatoes on the traeger June 03, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (

ESTA

【baked potatoes on the traeger】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference


), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Goldman Sachs 41

【baked potatoes on the traeger】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference


st

【baked potatoes on the traeger】ESTA Announces Participation in the Goldman Sachs Global Healthcare Conference


Annual Global Healthcare Conference Webcast, which is being held June 9-11, 2020. Mr. Chacón-Quirós and Ms. Gaeta are scheduled to speak to conference attendees at 3:00pm ET on Wednesday, June 10, 2020.


A live webcast of the presentation will be available to all interested parties on the Establishment Labs investor relations website at


investors.establishmentlabs.com


. An archived version of the webcast will be available on the same website following the completion of the event.


About Establishment Labs


Establishment Labs Holdings Inc. (


ESTA


) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites that are compliant with ISO13485:2016, FDA 21 CFR 820 under the MDSAP program, and are currently commercially available in more than 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs received approval for an investigational device exemption (IDE) from the FDA and initiated the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, Establishment Labs’ product and technologies portfolio includes the Divina® 3D Simulation System and other products and services. Please visit our website for additional information at


www.establishmentlabs.com


.


Investor/Media Contact:


David K. Erickson


Establishment Labs Holdings Inc.


949-447-6671


[email protected]


View comments


本文地址:http://acnida.hotelcrush.net/news/09e399987.html
版权声明

本文仅代表作者观点,不代表本站立场。
本文系作者授权发表,未经许可,不得转载。

全站热门

Fiat Chrysler postpones shareholders' meeting and resolution on dividend to late June

Ferrari (RACE) Q3 Earnings Beat Estimates

OneWater Marine Inc. Announces Fiscal Fourth Quarter and Full-Year 2020 Earnings Release Date and Conference Call Information

SNX or GWRE: Which Is the Better Value Stock Right Now?

Domino's Pizza (DPZ) is an Incredible Growth Stock: 3 Reasons Why

Labrador Iron Ore Royalty Corporation Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Song of Red Star Youth Music Project Show the Confidence of Chinese Young Generation

Is Burlington Stores (BURL) a Solid Growth Stock? 3 Reasons to Think Yes

友情链接